Maintaining weight loss after initially successful treatment remains a significant hurdle for individuals with obesity. Although medications like Ozempic and Wegovy have demonstrated remarkable efficacy in promoting weight reduction, sustaining that loss long-term often proves challenging. Now, a new clinical trial is investigating a different approach—a once-daily pill called setmelanotide—that aims to address this very problem by targeting the brain’s appetite control center. This research offers a potential new avenue for those struggling to keep weight off after completing initial obesity treatments, focusing on a different biological pathway than currently available drugs.
The challenge isn’t simply a matter of willpower. Physiological adaptations occur during weight loss that make it harder to maintain, including hormonal changes that increase hunger and decrease metabolism. Ozempic and Wegovy, both GLP-1 receptor agonists, work by mimicking a natural hormone that regulates appetite and blood sugar. They’ve shown impressive results, with some individuals losing up to 20% of their body weight, but long-term data on sustained weight management are still emerging. A study published in the New England Journal of Medicine in 2022 showed that after stopping semaglutide (Wegovy), participants regained a significant portion of the weight they had lost within a year . This underscores the need for additional strategies to support lasting weight management.
How Setmelanotide Works: Targeting the MC4 Receptor
Setmelanotide, developed by Rhythm Pharmaceuticals, takes a different tack. It’s a melanocortin-4 receptor (MC4R) agonist. The MC4R plays a crucial role in regulating energy balance and appetite. Genetic defects in the MC4R pathway are a common monogenic cause of obesity, meaning a single gene mutation can significantly increase a person’s risk. Setmelanotide aims to activate this receptor, essentially “resetting” the brain’s appetite control system. It’s already approved by the FDA for treating obesity caused by specific genetic defects in the MC4R pathway, but this new trial explores its potential for broader use in individuals who have lost weight with other therapies and are struggling to maintain it.
The Phase 2 clinical trial, detailed in a press release from Rhythm Pharmaceuticals , involved 48 participants who had previously lost at least 5% of their body weight with intensive lifestyle interventions or anti-obesity medications (including Ozempic or Wegovy). Participants were randomized to receive either setmelanotide or a placebo for 52 weeks. The primary endpoint of the trial was the proportion of participants who regained less than 5% of their weight lost during the initial weight loss phase.
Trial Results: Promising Data, But Further Research Needed
Preliminary results indicate that a significantly higher percentage of participants treated with setmelanotide maintained their weight loss compared to those on placebo. Specifically, 78% of participants taking setmelanotide regained less than 5% of their lost weight, compared to 29% in the placebo group. The average weight regain in the setmelanotide group was approximately 1.3 kg (2.9 lbs), while the average regain in the placebo group was 8.3 kg (18.3 lbs). These findings suggest that setmelanotide could be a valuable tool in preventing weight regain after initial weight loss.
Though, it’s important to note that this is a Phase 2 trial, meaning it’s designed to assess the drug’s safety and efficacy in a relatively small group of participants. Larger, Phase 3 trials are needed to confirm these findings and to evaluate the long-term effects of setmelanotide. The trial similarly reported some side effects, including skin darkening, nausea and injection site reactions, though these were generally mild to moderate in severity.
Who Might Benefit and What’s Next?
If approved for broader use, setmelanotide could be particularly beneficial for individuals who have successfully lost weight but are struggling with the physiological challenges of maintaining that loss. It’s not intended as a first-line treatment for obesity, but rather as a potential adjunct therapy for those who have already made significant progress. The drug’s mechanism of action—targeting the MC4R—suggests it might be most effective in individuals whose weight regain is driven by disruptions in appetite regulation.
Rhythm Pharmaceuticals is planning to initiate a Phase 3 clinical trial to further evaluate setmelanotide for weight maintenance. The company anticipates beginning this trial in the first half of 2024. The FDA will require data from these larger trials before considering approval for this expanded indication. For individuals currently using Ozempic or Wegovy, or considering these medications, it’s crucial to discuss long-term weight management strategies with their healthcare provider, including lifestyle modifications and potential future therapies like setmelanotide.
The ongoing research into setmelanotide represents a significant step forward in our understanding of obesity and the complex mechanisms that govern weight regulation. Addressing the challenge of weight maintenance is critical for improving the long-term health and well-being of millions of people affected by this chronic condition. The development of new therapies that target different pathways in the brain’s appetite control system offers hope for more effective and sustainable weight management solutions.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have you or someone you grasp struggled with maintaining weight loss? Share your experiences and thoughts in the comments below. Please also share this article with anyone who might find this information helpful.
Worth a look
